What Huons Global Co does

Huons Global Co is a South Korea-based KOSDAQ-listed holding company (ticker: 195940) operating a diversified healthcare group through five publicly listed subsidiaries — Huons, Humedix, Huons BioPharma, Huons Meditech, and HuM&C — plus PanGen Biotech (acquired December 2024) and nine additional affiliates. The group generates consolidated revenue of KRW 813.5 billion in FY2024 (+7.3% YoY) across four primary verticals: pharmaceuticals (anesthetics, chronic disease drugs, ophthalmic/otological solutions, CMO at Jecheon facilities), medical aesthetics (Elravie and Revolline HA dermal fillers, Hutox botulinum toxin, skin boosters), medical devices (DermaShine Pro auto-injectors, ASADAL-M1 lithotripters, endoscope reprocessors), and consumer health functional foods (Menolacto menopause probiotics, Merit-C vitamins, Elruby supplements, Innerset). Customer reach extends to hospitals, aesthetic clinics, and consumers across 19+ countries for fillers and 15+ countries for botulinum toxin, with regional operations in Tokyo (Huons Japan), Los Angeles (Huons USA), and a Vietnam manufacturing facility under construction.

The group's core technological differentiation rests on proprietary hyaluronic acid crosslinking platforms (Hi-B and HiVE) used in Humedix fillers, Huonslab's recombinant human hyaluronidase HyDIFFUZE (HLB3-002) produced via CHO cell culture with demonstrated bioequivalence to Halozyme's ENHANZE platform, and bio-polymer application technology underlying the HUMIA sustained-release osteoarthritis injection. Manufacturing is concentrated in Jecheon (Huons Plant 2 for ophthalmics/injectables; Humedix for HA fillers) and Seongnam (Humedix, Huons M&C glass and cosmetic accessories), with R&D at the Huons Central Research Center in Cheongju and a new integrated R&D center under construction in Pangyo. Regulatory approvals span Korea MFDS, EU CE, US FDA (ASADAL-M1), China NMPA, Taiwan TFDA, Thailand TFDA, Russia, and Syria. Hydizyme (BLA submitted 2025) and oral peptide therapeutics (selected for KRW 8.13 billion government R&D project in 2024) signal expansion into biologics and metabolic disease.

Revenue mechanics combine enterprise field sales to hospitals and aesthetic clinics, channel-partner-mediated international distribution (MnB Thai covering 1,500+ Thai clinics, Talia Medical in Syria, regional partners across Saudi Arabia, Lebanon, China, Brazil, EU, Russia), and direct-to-consumer channels including Naver Smart Store, Huonsmall.com, and TV home shopping partnerships with Lotte and Hyundai for cosmetics and health functional foods. The group has undergone significant portfolio reshaping in 2024-2026, including the PanGen Biotech acquisition (December 2024), the merger of Huons with Huons Life Sciences (June 2026), and the announced merger of Huons with Huonslab (May 2026) motivated by Huonslab's capital impairment. The Co-CEO leadership structure reinstated in March 2025 with Chairman Yoon Sung-tae returning alongside Song Soo-young coincides with equity transfers to the chairman's three sons, indicating active multi-generational succession planning.

Name

Huons Global Co

Legal name

주식회사 휴온스글로벌 (Huons Global Co., Ltd.)

Website

https://huonsglobal.com

Company type

Public

Founded year

1965

Operating status

Operating

Headcount range

251–500 employees

Short description

Huons Global Co is a KOSDAQ-listed South Korean healthcare holding company operating pharmaceuticals, medical aesthetics (HA fillers, botulinum toxin), medical devices, and consumer health functional foods through five listed subsidiaries, serving hospitals, clinics, and consumers across 19+ countries.

Ownership category

akta.pro rank

Headquarters

HQ city

Seongnam

HQ country

South Korea

HQ region

Asia

Offices10 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Operations, Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. Huons (Pharmaceuticals): Revenue from prescription pharmaceuticals including anesthetics, chronic disease medications, and ophthalmic/otological products. Export of anesthetics to the US and other markets. Includes contract manufacturing (CMO) for third-party pharmaceuticals at Jecheon facilities.
2. Humedix (Aesthetic & CMO): Revenue from hyaluronic acid dermal fillers (Elravie, Revolline), cosmetics (Elravie cosmetic line), and osteoarthritis injections (HUMIA, High Hyal Plus). Includes CMO for expert pharmaceuticals and joint arthritis injectables. Geographic exports to China, Brazil, Middle East, Southeast Asia, Europe.
3. Huons (Health Functional Foods): Revenue from consumer health functional foods including menopausal probiotics (Menolacto), vitamins (Merit-C), immunity products, and omega-3 supplements sold via home shopping, Naver Smart Store, e-commerce, and E-Mart.
4. Huons Meditech (Medical Devices): Revenue from medical devices including DermaShine Pro mesotherapy injectors, ASADAL-M1 lithotripters, URO-UEMXD, IMPO88 Plus, endoscope reprocessors (Huen Single), and DermaShine Duo RF. Global exports to Europe, China, Middle East, South America.
5. Huons BioPharma (Botulinum Toxin): Revenue from botulinum toxin products (Hutox) approved in 15 countries including Russia, Southeast Asia, Iraq. Exports to China under regulatory approval process. Strategic partnership with VERNI Aesthetics for MRC101 aesthetic product.
6. Huons N (Life Care): Revenue from health functional food manufacturing and brand operations including CogniCore, Elruby supplements, organic products, and functional beverages. Includes CMO of health supplements via Biologics subsidiary.

Pricing tiers

Go-to-market motion4 records

Distribution channels8 records

Marketing channels9 records

Core offering

Huons Global Co is a KOSDAQ-listed holding company operating a total healthcare group of five listed subsidiaries and nine affiliates that manufactures and sells prescription pharmaceuticals (anesthetics, ophthalmic, chronic disease), hyaluronic acid dermal fillers, botulinum toxin, medical devices (lithotripters, auto-injectors, endoscope reprocessors), biopharmaceuticals (recombinant human hyaluronidase, biosimilars, CDMO services), and consumer health functional foods and derma cosmetics. The group is a vertically integrated manufacturer with its own R&D, GMP-certified production facilities in Jecheon, Seongnam, and Vietnam, and an export network covering 19+ countries for fillers and 15+ countries for botulinum toxin.

Product overview

Huons Global Co is a total healthcare group operating multiple subsidiaries across pharmaceuticals, medical devices, health functional foods, and derma cosmetics. The company's core products include: Elravie hyaluronic acid fillers by Humedix for aesthetic applications; Dermashine Pro and related medical devices by Huons Meditech for drug delivery and aesthetic procedures; HyDIFFUZE recombinant human hyaluronidase platform by Huonslab for drug diffusion and subcutaneous injection conversion; HUMIA sustained-release osteoarthritis injection; Huons BioPharma's botulinum toxin products; PanGen Biotech's biosimilars and CDMO services; and consumer health brands including Elruby, InnerSet, MeritC supplements, and Menolacto probiotics sold through the Huonsmall e-commerce platform. The group operates under a holding company structure established in 2016.

Differentiator

Problem solved

Functional benefit

Brands

• Elravie (엘라비에): Humedix's premium hyaluronic acid dermal filler brand; includes Elravie Premier, Elravie Plus, and Melarution product lines for aesthetic applications
• Innerset (이너셋)
• DermaShine (더마샤인)
• ASADAL (아사달)
• Menolacto (메노락토)
• Merit C (메리트C)
• HyDIFFUZE (하이디퓨즈)
• HUMIA (휴미아)
• Elruby (엘루비)

Products and services

• Elravie HA Dermal Fillers Premium hyaluronic acid dermal filler brand by Humedix for facial contouring, wrinkle reduction, and skin rejuvenation. Used by aesthetic clinics, dermatology centers, and plastic surgery hospitals in 19+ countries including China, Brazil, EU, Russia, Thailand.
• DermaShine Pro Mesotherapy Auto-Injector Pressure-sensitive automatic mesotherapy injector for precise drug infusion of hyaluronic acid skin boosters. Compatible with 32G, 34G, and 9-pin sterile needles. Cumulative global sales exceeded 20,000 units by end of 2024.
• ASADAL-M1 Lithotripter Electromagnetic extracorporeal shock wave (ESWL) device for non-invasive kidney stone fragmentation. Features US FDA and CE certifications, allowing same-day treatment and discharge with high efficacy and safety.
• HUMIA Sustained-Release Osteoarthritis Injection Sustained-release osteoarthritis injection by Humedix providing 6-month efficacy from a single dose. Uses proprietary biopolymer application technology combining high-purity hyaluronic acid with structure similar to normal human synovial fluid.
• HyDIFFUZE (Recombinant Human Hyaluronidase) Recombinant human hyaluronidase (HLB3-002) platform technology by Huonslab produced via CHO cell culture with patented manufacturing technology. Used as a drug diffusion agent for subcutaneous injection conversion, with applications in aesthetics, dermatology, pain management, and edema treatment. Has equivalent pharmacokinetics to Halozyme's Hylenex.
• Hutox Botulinum Toxin Type A botulinum toxin product by Huons BioPharma approved in 15+ countries for aesthetic and therapeutic applications. Strategic partnership with VERNI Aesthetics for MRC101 aesthetic product development.
• Elruby Health Functional Foods Premium health functional food brand including Immunity Probiotics Waisela, Phosphatidylserine Zinko (brain health), and other supplements. Distributed through Huonsmall.com, Naver Smart Store, home shopping, and E-Mart retail.
• InnerSet Health Functional Foods Health functional food brand by Huons Foodience featuring low-molecular fish collagen, ginseng jelly sticks, and various dietary supplements. Sold through Naver Brand Store and other consumer channels.
• Menolacto Menopause Probiotics Menopause care probiotic brand featuring premium and pro versions with L.acidophilus YT1 strain. Cumulative sales exceeded KRW 130 billion as of 2023. Sold through home shopping, Naver Smart Store, and retail channels.
• Elravie Melarutin Cushion (Derma Cosmetics) Consumer derma cosmetic cushion foundation featuring melasma care, 150-hour moisturizing, and SPF50+ PA++++ sun protection. Sold via Lotte Home Shopping and online channels.
• Huen Single Endoscope Reprocessor Automatic endoscope washer/disinfector using single-use peracetic acid disinfectant solution. Prevents biofilm formation and sterilizes all pathogenic microorganisms including spores within 5 minutes. Used in hospitals and clinics for endoscope reprocessing.
• PanGen Biotech CDMO/Biosimilars Services Biologics company under Huons Group specializing in biosimilars and contract development and manufacturing (CDMO) services. Uses PanGen CHO-TECH platform for EPO biosimilar manufacturing and biopharmaceutical process characterization. Signed KRW 1.9 billion CMO contract with CHA Vaccine Institute in 2025.
• Huons Meditech Urological Device Portfolio Urological medical device portfolio including URO-UEMXD (combined ultrasound + shockwave for urinary stones), IMPO88 Plus (shockwave device for erectile dysfunction), and DermaShine Duo RF (RF + drug infusion for aesthetics).
• Huons Contract Manufacturing (CMO) Services Contract manufacturing services for third-party pharmaceuticals at Jecheon facilities, including injectable product lines, ophthalmic and otological products, and biopharmaceuticals. Serves partner pharmaceutical companies under GMP standards.
• Revolline HA Fillers HA filler product line by Humedix using HiVE (High Viscoelasticity) Technology, including Revolline Hara-L. Distributed internationally including in Thailand, China, EU, and other markets with TFDA and NMPA approvals.

Quantifiable outcome

• Humedix achieved USD 24 million / KRW 33.7 billion in annual export revenue, a significant milestone within four years of receiving the $10M Export Tower Award.
• +4 more outcomes

Named customers8 records

Segments5 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

Seven partnerships are on record, tiered core and minor.

• Talia Medical LLC (Syria)coreChannel Partner/ Reseller/ Distributor · 12 January 2026Humedix partnered with Talia Medical LLC, a Syrian medical device and aesthetic product importer and distributor, for distribution of Elravie Plus 3 HA filler products (Elravie Deepline Plus 1ml, Elravie Ultra Volume Plus 2ml, Elravie Light Plus 1ml) following Syrian official product approval. Talia Medical will support stable supply and smooth market entry leveraging its local network and market expertise, targeting Syrian medical professionals and consumers.
• Dubai Derma 2025 Partners (Saudi Arabia, Lebanon, Syria)coreChannel Partner/ Reseller/ Distributor · 17 April 2025At Dubai Derma 2025 exhibition, Humedix signed HA filler Elravie supply contracts covering Saudi Arabia, Lebanon, and Syria markets. The Middle East expansion builds on existing Syrian partnership with Talia Medical. Huons Meditech showcased Dermashine Pro and Huons BioPharma promoted Hutox botulinum toxin products (approved in 15 countries including Iraq in Middle East) at the exhibition.
• CHA Vaccine InstitutecoreStrategic or Co-development Partner · 2 April 2025PanGen Biotech signed a KRW 1.9 billion CMO contract with CHA Vaccine Institute, a KOSDAQ-listed company developing next-generation vaccines and immunotherapy drugs using immune-boosting platform technology. CHA Vaccine Institute outsourced a biopharmaceutical project worth KRW 1.9 billion to PanGen. The companies have collaborated since early stages including joint development and PanGen's previous CDMO contract. PanGen aims to strengthen its position as a global biopharmaceutical development company through this partnership under Huons Group.
• PanGen BiotechcoreStrategic or Co-development Partner · 5 March 2025PanGen Biotech, a Huons Group affiliate specializing in biopharmaceuticals, signed a KRW 800 million research service contract with Huonslab for biopharmaceutical process characterization. This service designs standard processes for commercial-scale production of biopharmaceuticals, essential for product license applications. PanGen uses its CHO-TECH platform and biopharmaceutical productization technology for CDMO services. PanGen previously produced clinical samples for Huonslab in 2023 and conducted validation for product approval in 2024. PanGen joined Huons Group in December 2024 and achieved record revenue of KRW 14.7 billion in 2024.
• MnB Thai (Thailand)coreChannel Partner/ Reseller/ Distributor · 3 February 2025Humedix partnered with MnB Thai, a specialized aesthetic distributor, for distribution of three HA filler products in Thailand (Elravie Premier Soft-L, Elravie Premier Deep Line-L, Revolline Hara-L/Export name: Charmifil-Mild) following TFDA approval. MnB Thai supplies products to over 1,500 hospitals and clinics across Thailand. Humedix expects to rapidly expand market share leveraging MnB Thai's established distribution network and differentiated sales and marketing strategy.
• VERNI AestheticscoreStrategic or Co-development Partner · 27 November 2024Huons BioPharma signed a strategic investment agreement with VERNI Aesthetics to strengthen its aesthetics business. Through this investment, Huons BioPharma acquired commercialization and manufacturing rights to MRC101, an aesthetic product. The partnership aims to diversify Huons BioPharma's product lineup beyond its flagship botulinum toxin (Hutox), with plans for joint development of MRC101's follow-on pipeline. VERNI Aesthetics will continue advancing the MRC101 pipeline with Huons Group through open-innovation collaboration.
• Chungnam National University (Prof. Kwon Hyo-jung)minorStrategic or Co-development Partner · 1 January 2024Huons collaborated with Chungnam National University since 2017 to develop Quisqualis Extract Powder for prostate health. Technology was transferred from the university (Prof. Kwon Hyo-jung of Veterinary Medicine), and Huons succeeded in developing and commercializing the technology. This collaboration led to US patent registration and multiple awards for the product.

Scale indicators12 records

Recent moves10 records

Expansion highlights7 records

Broad incumbents

• Yuhan Corporation: Large Korean pharmaceutical manufacturer with consumer health and OTC products; comparable as a Korean pharma with both prescription and consumer health franchises and growing international presence.
• LG Chem: Korean chemical and life sciences conglomerate with LG Chem Life Sciences (pharma, biosimilars, vaccines); comparable as a large Korean diversified healthcare player with both pharma and biologics franchises.
• GC Biopharma: Korean biopharmaceutical company (formerly Green Cross) with vaccines, plasma products, and biosimilars; relevant comparable for Huons' biologics/CDMO ambitions via PanGen Biotech.
• Dong-A ST: Mid-sized Korean pharmaceutical company with specialty pharma, OTC, and consumer health products; comparable in scope of prescription + consumer health dual franchise.
• Galderma: Global dermatology and aesthetics company (fillers, toxin, skincare); relevant incumbent comparable for Humedix's HA filler and aesthetic injectable business in international markets.

Direct peers

• Daewoong Pharmaceutical: Korean pharmaceutical company with Nabota botulinum toxin and a portfolio of fillers and aesthetics products; competes directly with Huons BioPharma's Hutox and Humedix's Elravie in both domestic and export markets including Southeast Asia.
• Hanmi Pharmaceutical: Korean pharma company with diversified prescription drug pipeline and aesthetics/specialty products; comparable model of Korean pharma expansion into multiple therapeutic areas and global markets.
• Halozyme Therapeutics: US biotech behind the ENHANZE recombinant human hyaluronidase platform (Hylenex); HyDIFFUZE is explicitly positioned against ENHANZE, making Halozyme the most direct technology competitor for Huonslab's lead asset.
• Medytox: Korean biopharmaceutical company developing botulinum toxin (Medytoxin/Innotox) and HA fillers; one of the closest direct competitors to Huons BioPharma and Humedix in the Korean and global aesthetics markets.

Emerging players

• PharmaResearch: Korean biotech known for Rejuran (PN/ polynucleotide) skin regeneration products; relevant emerging Korean aesthetics peer competing in the same dermatology/aesthetic clinic channel as Elravie.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/channel/UC211PAceLoNC5QZNb4nuKWw
• Facebookfacebook.com/huons
• LinkedInkr.linkedin.com/company/huonsglobal
• Instagraminstagram.com/huonsn_official

Compliance11 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Subsidiaries13 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Huons Global Co